HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics

Mohamed Atta, Michelle M. Estrella, Michael Kuperman, Matthew C. Foy, Derek M Fine, Lorraine C Racusen, Gregory M Lucas, George W. Nelson, Andrew C. Warner, Cheryl A. Winkler, Jeffrey B. Kopp

Research output: Contribution to journalArticle

Abstract

Recently, an association was found between nondiabetic kidney disease in African Americans and two independent sequence variants in the APOL1 gene, encoding apolipoprotein L1. In this study we determined the frequency of APOL1 risk variants in patients with biopsy-proven HIV-associated nephropathy (HIVAN) and distinctive pathological characteristics potentially driven by those risk variants. Among 76 patients with HIVAN, 60 were successfully genotyped for APOL1 G1 and G2 polymorphisms. In this cohort, 37 had two risk alleles, 18 were heterozygous, and 5 had neither risk variant. There were no differences in the pathological findings of HIVAN and the number of APOL1 risk alleles. Further, the progression to end-stage kidney disease or death did not differ by the number of risk alleles. Median renal survival was 9.3 months in patients with zero or one risk allele compared to 11.7 months in patients with two APOL1 risk alleles. Thus, our study suggests that although the majority of African-American patients with HIVAN have two APOL1 risk alleles other as yet unknown factors in the host, including genetic risk variants and environmental or viral factors, may influence the development of this disorder in those with zero or one APOL1 risk allele.

Original languageEnglish (US)
Pages (from-to)338-343
Number of pages6
JournalKidney International
Volume82
Issue number3
DOIs
StatePublished - Aug 1 2012

Fingerprint

AIDS-Associated Nephropathy
Apolipoproteins
Alleles
Genes
African Americans
Kidney Diseases
Chronic Kidney Failure

Keywords

  • APOL1
  • end-stage kidney disease
  • HIV-associated nephropathy

ASJC Scopus subject areas

  • Nephrology

Cite this

HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. / Atta, Mohamed; Estrella, Michelle M.; Kuperman, Michael; Foy, Matthew C.; Fine, Derek M; Racusen, Lorraine C; Lucas, Gregory M; Nelson, George W.; Warner, Andrew C.; Winkler, Cheryl A.; Kopp, Jeffrey B.

In: Kidney International, Vol. 82, No. 3, 01.08.2012, p. 338-343.

Research output: Contribution to journalArticle

Atta, Mohamed ; Estrella, Michelle M. ; Kuperman, Michael ; Foy, Matthew C. ; Fine, Derek M ; Racusen, Lorraine C ; Lucas, Gregory M ; Nelson, George W. ; Warner, Andrew C. ; Winkler, Cheryl A. ; Kopp, Jeffrey B. / HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. In: Kidney International. 2012 ; Vol. 82, No. 3. pp. 338-343.
@article{4e3a7920155b44bca9ec0924ffae147f,
title = "HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics",
abstract = "Recently, an association was found between nondiabetic kidney disease in African Americans and two independent sequence variants in the APOL1 gene, encoding apolipoprotein L1. In this study we determined the frequency of APOL1 risk variants in patients with biopsy-proven HIV-associated nephropathy (HIVAN) and distinctive pathological characteristics potentially driven by those risk variants. Among 76 patients with HIVAN, 60 were successfully genotyped for APOL1 G1 and G2 polymorphisms. In this cohort, 37 had two risk alleles, 18 were heterozygous, and 5 had neither risk variant. There were no differences in the pathological findings of HIVAN and the number of APOL1 risk alleles. Further, the progression to end-stage kidney disease or death did not differ by the number of risk alleles. Median renal survival was 9.3 months in patients with zero or one risk allele compared to 11.7 months in patients with two APOL1 risk alleles. Thus, our study suggests that although the majority of African-American patients with HIVAN have two APOL1 risk alleles other as yet unknown factors in the host, including genetic risk variants and environmental or viral factors, may influence the development of this disorder in those with zero or one APOL1 risk allele.",
keywords = "APOL1, end-stage kidney disease, HIV-associated nephropathy",
author = "Mohamed Atta and Estrella, {Michelle M.} and Michael Kuperman and Foy, {Matthew C.} and Fine, {Derek M} and Racusen, {Lorraine C} and Lucas, {Gregory M} and Nelson, {George W.} and Warner, {Andrew C.} and Winkler, {Cheryl A.} and Kopp, {Jeffrey B.}",
year = "2012",
month = "8",
day = "1",
doi = "10.1038/ki.2012.111",
language = "English (US)",
volume = "82",
pages = "338--343",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics

AU - Atta, Mohamed

AU - Estrella, Michelle M.

AU - Kuperman, Michael

AU - Foy, Matthew C.

AU - Fine, Derek M

AU - Racusen, Lorraine C

AU - Lucas, Gregory M

AU - Nelson, George W.

AU - Warner, Andrew C.

AU - Winkler, Cheryl A.

AU - Kopp, Jeffrey B.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Recently, an association was found between nondiabetic kidney disease in African Americans and two independent sequence variants in the APOL1 gene, encoding apolipoprotein L1. In this study we determined the frequency of APOL1 risk variants in patients with biopsy-proven HIV-associated nephropathy (HIVAN) and distinctive pathological characteristics potentially driven by those risk variants. Among 76 patients with HIVAN, 60 were successfully genotyped for APOL1 G1 and G2 polymorphisms. In this cohort, 37 had two risk alleles, 18 were heterozygous, and 5 had neither risk variant. There were no differences in the pathological findings of HIVAN and the number of APOL1 risk alleles. Further, the progression to end-stage kidney disease or death did not differ by the number of risk alleles. Median renal survival was 9.3 months in patients with zero or one risk allele compared to 11.7 months in patients with two APOL1 risk alleles. Thus, our study suggests that although the majority of African-American patients with HIVAN have two APOL1 risk alleles other as yet unknown factors in the host, including genetic risk variants and environmental or viral factors, may influence the development of this disorder in those with zero or one APOL1 risk allele.

AB - Recently, an association was found between nondiabetic kidney disease in African Americans and two independent sequence variants in the APOL1 gene, encoding apolipoprotein L1. In this study we determined the frequency of APOL1 risk variants in patients with biopsy-proven HIV-associated nephropathy (HIVAN) and distinctive pathological characteristics potentially driven by those risk variants. Among 76 patients with HIVAN, 60 were successfully genotyped for APOL1 G1 and G2 polymorphisms. In this cohort, 37 had two risk alleles, 18 were heterozygous, and 5 had neither risk variant. There were no differences in the pathological findings of HIVAN and the number of APOL1 risk alleles. Further, the progression to end-stage kidney disease or death did not differ by the number of risk alleles. Median renal survival was 9.3 months in patients with zero or one risk allele compared to 11.7 months in patients with two APOL1 risk alleles. Thus, our study suggests that although the majority of African-American patients with HIVAN have two APOL1 risk alleles other as yet unknown factors in the host, including genetic risk variants and environmental or viral factors, may influence the development of this disorder in those with zero or one APOL1 risk allele.

KW - APOL1

KW - end-stage kidney disease

KW - HIV-associated nephropathy

UR - http://www.scopus.com/inward/record.url?scp=84863810792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863810792&partnerID=8YFLogxK

U2 - 10.1038/ki.2012.111

DO - 10.1038/ki.2012.111

M3 - Article

C2 - 22495294

AN - SCOPUS:84863810792

VL - 82

SP - 338

EP - 343

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -